Efficacy of adjunctive brexpiprazole in patients with major depressive disorder: A clinical overview

Current Psychiatry Reviews

Volumn 12, Issue 3, 2016, Pages 291-301

  Thase, Michael E ^a   Zhang, Peter ^b   Skuban, Aleksandar ^b   Hobart, Mary ^b   Weiss, Catherine ^b   Weiller, Emmanuelle ^c   Nelson, James C ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c H LUNDBECK A S   (Denmark)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjunctive therapy; Antipsychotics; Brexpiprazole; Efficacy; Major depressive disorder

Indexed keywords

BREXPIPRAZOLE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADJUVANT THERAPY; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION INVENTORY; DOSE RESPONSE; DRUG EFFICACY; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; METABOLISM; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHEEHAN DISABILITY SCALE;

EID: 85006850891     PISSN: 15734005     EISSN: 18756441     Source Type: Journal    
DOI: 10.2174/1573400512999160901094451     Document Type: Review

References (31)

1. Epstein I, Szpindel I, Katzman MA. Pharmacological approaches to manage persistent symptoms of major depressive disorder: rationale and therapeutic strategies. Psychiatry Res 2014; 220(Suppl 1): S15-S33.
2. Wright BM, Eiland EH, III, Lorenz R. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Pharmacotherapy 2013; 33: 344-59.
3. Kessler RC. The costs of depression. Psychiatr Clin North Am 2012; 35: 1-14.
4. Charlson FJ, Moran AE, Freedman G, et al. The contribution of major depression to the global burden of ischemic heart disease: a comparative risk assessment. BMC Med 2013; 11: 250.
5. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013; 10: e1001547.
6. Hofmann M, Kohler B, Leichsenring F, Kruse J. Depression as a risk factor for mortality in individuals with diabetes: a metaanalysis of prospective studies. PLoS One 2013; 8: e79809.
7. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the global burden of disease study 2010. PLoS One 2015; 10: e0116820.
8. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longerterm outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-17.
9. Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009; 70(Suppl 6): 16-25.
10. Connolly KR, Thase ME. If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011; 71: 43-64.
11. Mauskopf JA, Simon GE, Kalsekar A, Nimsch C, Dunayevich E, Cameron A. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety 2009; 26: 83-97.
12. Patkar AA, Pae CU. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs 2013; 27(Suppl 1): S29-S37.
13. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980-91.
14. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013; 10: e1001403.
15. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014; 350: 589-604.
16. Thase M, Fava M, Hobart M, et al. Efficacy of adjunctive OPC-34712 across multiple outcome measures in major depressive disorder: A phase II, randomized, placebo-controlled study. Neuropsychopharmacology 2011; 36: S302-S304.
17. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 2015; 76: 1224-31.
18. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 2015; 76: 1232-40.
19. Nelson JC, Zhang P, Skuban A, et al. Overview of Short-Term and Long-Term Safety of Brexpiprazole in Patients with Major Depressive Disorder and Inadequate Response to Antidepressant Treatment. Curr Pscy Rev 2016; 12(3): Epub ahead of print.
20. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Text Revision. Washington DC: American Psychiatric Association; 2000.
21. Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M. RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther 2010; 16: 322-5.
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
23. Thase ME, Trivedi MH, Nelson JC, et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry 2008; 10: 440-7.
24. Guy W. ECDEU Assessment Manual for Psychopharmacology (revised). In: Hamilton M, Ed. Hamilton anxiety scale. US Department of Health, Education, and Welfare publication (ADM) 76-338, Rockville, MD: National Institute of Mental Health; 1976. pp 193-8.
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
26. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996; 11(Suppl 3): 89-95.
27. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26: 477-86.
28. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-5.
29. Duru G, Fantino B. The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin 2008; 24: 1329-35.
30. Montgomery SA, Moller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol 2009; 24: 111-8.
31. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358: 55-68.